Published On : September 2026
The twelve companies covered in this report are grouped by genuine business function rather than presented as a single undifferentiated list: nanoformulation excipient and materials providers, contract development and manufacturing organisations, pharmaceutical and biotechnology innovators, and specialty nanomedicine-focused developers.
Every company receives equal factual treatment in this report regardless of the order in which it appears; grouping is based on business type, not on any assessment of relative market position.
Geographic footprint, product and service portfolio, distribution and go-to-market approach, financials, certifications, partnerships, research and development activity and recent developments are profiled for each company in the full report, giving buyers a consistent basis for comparison across all four business types.
This structure is designed so that a reader comparing, for example, an upstream materials provider against a specialty nanomedicine-focused developer is comparing like with like on business function first, rather than assuming every covered company competes head to head in the same commercial role.
Buyers using this report to scope a licensing, outsourcing or supply relationship typically start from the business type most relevant to their own need, an excipient supplier for materials sourcing, a contract development and manufacturing organisation for production capability, or a pharmaceutical innovator or specialty developer for a potential licensing or co-development partner, before comparing specific companies within that group and weighing the specific factors most relevant to their own development stage and business model.
The overall market these companies operate within is covered in full on the nanoformulation bioavailability pain treatment market overview.
Evonik Industries AG, BASF SE, Ashland Global Holdings and Gattefosse supply the specialty lipid, polymer and excipient materials that nanoformulation developers build their platforms around, positioning these companies as upstream materials providers to the broader nanoformulation development chain rather than as direct pain treatment developers themselves.
Evonik Industries AG and BASF SE are both headquartered in Germany, reflecting the country's long-standing position as a European specialty chemicals and pharmaceutical materials hub, while Ashland Global Holdings is headquartered in the United States and Gattefosse in France.
Materials providers in this group typically serve multiple nanomedicine applications beyond pain treatment specifically, supplying excipients and carrier materials used across a wide range of nanoscale drug delivery programmes in other therapeutic areas as well, which gives them a broader customer base than a company focused solely on pain treatment formulations.
Because these companies sell materials rather than finished pain treatment products, their commercial relationships typically run through formulation science and procurement teams at pharmaceutical companies, specialty drug developers and contract development and manufacturing organisations rather than through direct-to-clinician or direct-to-patient channels.
A materials provider's certifications and quality systems are a particularly important part of its profile in this group, since a nanoformulation developer's own regulatory submission depends in part on the documentation its upstream materials suppliers can provide.
Long-standing customer relationships are common in this group, since switching an established excipient or lipid supplier partway through a development programme can require re-validating manufacturing and stability data, making materials selection an early and consequential decision in most nanoformulation programmes.
Evonik Industries AG and BASF SE both maintain broad specialty chemicals portfolios extending well beyond pharmaceutical excipients, while Ashland Global Holdings and Gattefosse maintain a closer relative focus on pharmaceutical, personal care and specialty ingredient supply, giving buyers a choice between broader diversified suppliers and more specialised ingredient partners.
Lonza Group AG and CordenPharma provide contract development and manufacturing services spanning nanoparticle production, formulation development and scale-up support for pharmaceutical companies and specialty drug developers that choose to outsource this capability.
Lonza Group AG is headquartered in Switzerland and CordenPharma is headquartered in Germany, and both operate manufacturing sites across multiple countries to serve pharmaceutical and biotechnology customers on a contract basis.
Both organisations offer services spanning early formulation development through commercial-scale manufacturing, which allows a customer to work with a single partner across multiple stages of a nanoformulation programme rather than transferring the work between different providers as it advances, reducing the technology-transfer risk that can arise when a programme changes manufacturing partners mid-development.
Manufacturing capacity for lipid nanoparticle and polymeric nanoparticle production specifically has become a point of active investment for both companies, reflecting broader demand for nanoparticle manufacturing capability across nanomedicine applications beyond pain treatment alone, a demand pattern that extends well past pain treatment into vaccine and other nanomedicine programmes as well.
A pharmaceutical company or specialty drug developer evaluating either organisation as a manufacturing partner typically looks beyond current capacity to planned capacity expansions as well, since a multi-year development and commercialisation timeline needs a manufacturing partner whose capacity plans extend at least as far as the programme's own.
These organisations sit at the center of the CDMO-based formulation outsourcing model described in the coverage of nanoformulation types these companies produce for pain treatment applications.
|
COMPETITIVE WATCH The presence of two major nanoparticle-focused contract development and manufacturing organisations alongside four upstream materials providers signals that a substantial share of nanoformulation production capability in this market sits outside the pharmaceutical companies actually bringing pain treatment products to market, a structural pattern worth watching as outsourcing activity continues to expand. |
Pfizer Inc., Moderna Inc. and AstraZeneca plc are large pharmaceutical and biotechnology organisations with broad drug development portfolios and prior experience working with nanoscale delivery platforms in other therapeutic contexts, positioning them as innovators capable of applying that platform experience to pain-focused reformulation work.
Pfizer Inc. is headquartered in the United States, Moderna Inc. is also headquartered in the United States, and AstraZeneca plc is headquartered in the United Kingdom, giving this group a footprint spanning both major North American and European pharmaceutical hubs.
All three organisations maintain research and manufacturing operations across multiple countries beyond their headquarters location, reflecting the multinational scale typical of large pharmaceutical and biotechnology companies operating across many therapeutic areas and geographies at once.
This multinational footprint gives each of the three organisations direct experience navigating regulatory review in multiple jurisdictions at once, a capability that is directly relevant to any nanoformulation-based pain treatment programme intended for commercialisation beyond a single country or region.
That multi-jurisdictional experience is one of the specific attributes a smaller specialty drug developer or emerging startup often seeks when evaluating one of these three organisations as a potential licensing or co-development partner, alongside the manufacturing and commercial infrastructure such large organisations typically bring to a partnership. A smaller partner gains access to that infrastructure without having to build it independently, which is often the deciding factor in favor of a licensing arrangement over pursuing in-house commercialisation alone, particularly for a platform still early enough in development that the eventual commercialisation cost has not yet been fully committed.
These organisations typically bring commercial infrastructure, regulatory experience and clinical development capability that smaller, more specialised organisations may still be building out, which is one reason they are often approached as licensing or co-development partners by specialty drug developers with an earlier-stage nanoformulation platform.
Their prior experience with nanoscale delivery platforms outside pain treatment, including in vaccine delivery and other therapeutic areas, gives them formulation science and manufacturing knowledge that can be adapted to pain-focused programmes without starting from a purely conceptual stage.
Because these companies operate across many therapeutic areas simultaneously, a pain-focused nanoformulation programme typically competes for internal resources and prioritisation alongside programmes in other categories, which is a dynamic that a smaller specialty organisation focused solely on pain treatment does not face in the same way.
Nanobiotix SA, Selecta Biosciences and Camurus AB are specialty organisations built specifically around nanomedicine and nanoparticle-based formulation platforms, giving them a narrower but deeper focus than the larger diversified pharmaceutical companies covered elsewhere in this report.
Nanobiotix SA is headquartered in France, Selecta Biosciences in the United States, and Camurus AB in Sweden, giving this specialty group a footprint spanning three separate European and North American markets.
Their concentrated focus on nanomedicine and nanoparticle-based platforms specifically, rather than a broad general pharmaceutical portfolio, is what distinguishes this group from the pharmaceutical and biotechnology innovators covered above.
As specialty drug developers by structure, this group is more likely than the larger diversified pharmaceutical companies to pursue licensing and co-development partnerships or to rely on contract development and manufacturing organisations for production capability, rather than maintaining fully integrated in-house manufacturing.
This structural difference is one reason a specialty nanomedicine-focused developer with a promising early-stage platform is often the counterparty in a licensing arrangement with one of the larger pharmaceutical and biotechnology innovators covered above, rather than a direct competitor pursuing the same commercialisation path independently.
Their positioning connects closely to the end-user and business-model structure described in the coverage of end-user and business model coverage for this market.
The report covers twelve companies grouped into four business types: nanoformulation excipient and materials providers, contract development and manufacturing organisations, pharmaceutical and biotechnology innovators, and specialty nanomedicine-focused developers.
Excipient and materials suppliers provide the specialty lipid, polymer and excipient materials that nanoformulation developers build their platforms around, serving as upstream providers to the broader nanoformulation development chain across multiple nanomedicine applications.
Contract development and manufacturing organisations provide nanoparticle production, formulation development and scale-up support for pharmaceutical companies and specialty drug developers that choose to outsource this capability rather than build it in-house.
Nanobiotix SA, Selecta Biosciences and Camurus AB are specialty organisations built specifically around nanomedicine and nanoparticle-based formulation platforms, distinguishing them from the larger diversified pharmaceutical companies also covered in this report.
Pfizer Inc. and Moderna Inc. are headquartered in the United States, while AstraZeneca plc is headquartered in the United Kingdom, giving this group a footprint spanning both major North American and European pharmaceutical hubs.
Materials suppliers sell the lipid, polymer and excipient inputs that other companies build nanoformulations around, and their commercial relationships run through procurement and formulation science teams rather than through direct pain treatment product commercialisation, making them a distinct business type from the innovators that bring finished products to market.
Specialty nanomedicine-focused developers concentrate specifically on nanomedicine and nanoparticle-based platforms and are more likely to rely on licensing, co-development or contract manufacturing partnerships, while larger pharmaceutical companies typically maintain broader, more diversified in-house development and commercial infrastructure.